Today: 9 June 2026
Verizon stock dips into 2026 as yields rise — what investors watch before VZ earnings
4 January 2026
2 mins read

Verizon stock dips into 2026 as yields rise — what investors watch before VZ earnings

NEW YORK, Jan 4, 2026, 15:17 ET — Market closed

  • Verizon shares last closed down 0.6% at $40.52 on Friday, underperforming a higher finish for the broader market.
  • Rate expectations are back in focus ahead of the U.S. jobs report (Jan. 9) and inflation data (Jan. 13).
  • Verizon is set to report fourth-quarter results on Jan. 30, with its next quarterly dividend payable Feb. 2.

Verizon Communications Inc. shares ended the first trading session of 2026 lower, closing down 0.6% on Friday at $40.52. The broader market finished higher, while Treasury yields climbed, keeping pressure on rate-sensitive dividend stocks.

That matters now because Verizon is widely treated as a “bond proxy” — a high-dividend stock that can trade like a bond when interest-rate expectations shift. Federal Reserve Bank of Philadelphia President Anna Paulson said on Saturday that additional rate cuts could take a while as policymakers assess the economy, according to a Reuters report. Reuters

The next week brings fresh tests for that rates narrative. The Labor Department is scheduled to release the Employment Situation report for December 2025 on Friday, Jan. 9, and the Consumer Price Index for December 2025 on Tuesday, Jan. 13, while the Federal Reserve’s January meeting is set for Jan. 27-28.

On the chart, Verizon is hovering around its 50-day moving average near $40.36, a widely watched trend indicator, and below its 200-day moving average around $42.45. The stock’s 52-week range runs from about $37.59 to $47.36, putting the late-December highs in view as resistance and the mid-$37 area as longer-term support.

Company-specific catalysts are lined up later this month. Verizon said it will report fourth-quarter 2025 earnings on Friday, Jan. 30, and host a webcast starting at 8:00 a.m. ET, with the press release and financial tables due at 6:30 a.m. ET.

Income investors also have a dividend date approaching. Verizon said in December it declared a quarterly dividend of 69 cents a share, payable on Feb. 2 to shareholders of record as of Jan. 12 — the record date is the cutoff for being on the company’s shareholder list to receive the payout.

When Verizon reports, traders will be listening for management’s read on wireless subscriber momentum, churn (the rate customers leave), and the cost of promotions used to win or retain customers. Investors will also scrutinize free cash flow — the cash left after expenses and capital spending — because it helps fund the dividend.

Competitive color will matter, too. Verizon’s results are often judged against AT&T and T-Mobile, particularly on pricing discipline and how much it costs to add customers in a mature U.S. wireless market.

Still, the setup has risks. Verizon’s dividend yield is roughly 6.8%, which can support demand in choppy markets, but that same yield makes the stock vulnerable if Treasury yields keep pushing higher or if promotions intensify and compress cash generation.

The next immediate catalyst for Verizon stock is Friday’s U.S. jobs report on Jan. 9, which can reset rate bets, before the company’s own spotlight on Jan. 30 when it reports results and updates its outlook.

Stock Market Today

  • J.M. Smucker Shares Rise After Earnings Beat Despite Sales Warning
    June 9, 2026, 10:05 AM EDT. J.M. Smucker shares rose 3.16% in pre-market trading after the company reported a 20% rise in adjusted earnings per share to $2.77, beating Wall Street estimates. The packaged-food firm grew net sales by 6% to $2.27 billion in Q4 but issued a cautionary note, forecasting a 3-4% decline in annual sales for fiscal 2027, below analysts' expectations of 1% growth. CEO Mark Smucker highlighted a focus on organic volume growth and profit improvement amid shifts in industry pricing strategies. Coffee sales drove quarterly results with a 12% retail sales increase but volume declines. The company flagged risks including consumer shifts to store brands, weight-loss drug impacts, and tariff fluctuations. Smucker's outlook balances lower sales with improved profitability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Tesco issues urgent “do not eat” recall for three pate lines after date-label error
Previous Story

Tesco issues urgent “do not eat” recall for three pate lines after date-label error

Oracle stock: 3 catalysts that could move ORCL when markets reopen
Next Story

Oracle stock: 3 catalysts that could move ORCL when markets reopen

Go toTop